FDA Refuses To Budge On Nitrosamines Compliance
Despite Complaints Of Possible Drug Shortages
Executive Summary
Industry requests for deadline extensions, short-duration adjustments and other accommodations go nowhere as FDA expresses concerns about nitrosamines’ mutagenic potency.